Perspectives on the Psychosocial Management of Oromandibular Dystonia

Abstract

Oromandibular dystonia (OMD) is a rare disorder of movement characterized by tonic muscle contractions that can result in involuntary, repetitive, and patterned muscle contractions of the lingual musculature, labial musculature, and/or muscles of mastication. As a result, dysarthria can be present that can lead to reduced speech intelligibility and have an adverse impact on psychosocial functioning. In this article, we will describe the clinical and speech characteristics of OMD and the various methods of treatment. Then we will introduce and describe patient-reported outcome measures that assess two aspects of psychosocial functioning: communicative participation and quality of life. We will describe the current state of knowledge as it relates to communicative participation and quality of life in this clinical population, and, finally, we will advocate that speech-language pathologists have a unique role in the care of individuals with OMD through the inclusion of patient-reported outcome measures to provide a comprehensive and holistic management plan.

Keywords

Oromandibular dystonia - dysarthria - psychosocial outcomes - communicative participation - quality of life

• References

• 1 Teemul TA, Patel R, Kanatas A, Carter LM. Management of oromandibular dystonia with botulinum A toxin: a series of cases. Br J Oral Maxillofac Surg 2016; 54 (10) 1080-1084
• 2 Gowers WR. A Manual of Diseases of the Nervous System. Vol. 2. 3rd ed. London : Churchill; 1899: 200
• 3 Meige H. Les convulsions de la face, une forme clinique de convulsions facile, bilaterale et mediane. Rev Neurol (Paris) 1910; 20: 437-443
• 4 Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000; 68 (02) 186-190
• 5 Merz RI, Deakin J, Hawthorne MR. Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life. Clin Otolaryngol 2010; 35 (05) 390-396
• 6 Tan EK. Oromandibular dystonia. In: Brin MF, Comella CL, Jankovic J. , eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 167-174
• 7 Bakke M, Larsen BM, Dalager T, Moller E. Oromandibular dystonia-functional and clinical characteristics: a report on 21 cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115 (01) e21-e26
• 8 Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355 (08) 818-829
• 9 Brin MF, Comella CL. Pathophysiology of dystonia. In: Brin MF, Comella CL, Jankovic J. , eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 5-10
• 10 Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton III LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3 (03) 188-194
• 11 Steinberger D, Topka H, Fischer D, Müller U. GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurology 1999; 52 (04) 877-879
• 12 Dworkin JP. Bite-block therapy for oromandibular dystonia. J Med Speech-Lang Pathol 1996; 4 (01) 47-56
• 13 Møller E, Bakke M, Dalager T. , et al. Somatosensory input and oromandibular dystonia. Clin Neurol Neurosurg 2013; 115 (07) 1141-1143
• 14 Lee KH. Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104 (04) 491-496
• 15 Papapetropoulos S, Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med 2006; 2 (47) 47
• 16 Gandhi YR. Oro-mandibular dystonia. Natl J Maxillofac Surg 2010; 1 (02) 150-152
• 17 Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res 1969; a; 12 (02) 246-269
• 18 Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 1969; b; 12 (03) 462-496
• 19 Kreisler A, Verpraet AC, Veit S. , et al. Clinical characteristics of voice, speech, and swallowing disorders in oromandibular dystonia. J Speech Lang Hear Res 2016; 59 (05) 940-949
• 20 Dykstra AD, Adams S, Jog M. The effect of botulinum toxin type A on speech intelligibility in lingual dystonia. J Med Speech-Lang Pathol 2007; 15 (02) 172-186
• 21 Golper LA, Nutt JG, Rau MT, Coleman RO. Focal cranial dystonia. J Speech Hear Disord 1983; 48 (02) 128-134
• 22 Weismer G, Yunusova Y, Bunton K. Measures to evaluate the effects of DBS on speech production. J Neurolinguist 2012; 25 (04) 74-94
• 23 Tinter R, Jankovich J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin MF, Hallet M, Jankovich J. , eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 1-12
• 24 Karp BI, Goldstein SR, Chen R, Samii A, Bara-Jimenez W, Hallett M. An open trial of clozapine for dystonia. Mov Disord 1999; 14 (04) 652-657
• 25 Blanchet PJ, Rompré PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont 2005; 18 (01) 10-19
• 26 Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000; 320 (7228): 161-165
• 27 Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001; 111 (02) 218-226
• 28 Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33 (03) 155-188
• 29 Kazerooni R, Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am J Health Syst Pharm 2015; 72 (04) 301-307
• 30 Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53 (08) 633-639
• 31 Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 2003; 60 (12) 2017-2018
• 32 Foote KD, Sanchez JC, Okun MS. Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology. Neurosurgery 2005; 56 (02) E415
• 33 Dykstra AD, Domingo Y, Adams SG, Jog M. Examining speech intelligibility and self- ratings of communicative effectiveness in speakers with oromandibular dystonia receiving botulinum toxin therapy. Canadian Journal of Speech Language Pathol Audiol 2015; 39 (04) 334-345
• 34 Page AD, Siegel L, Jog M. Self-rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections. Am J Speech Lang Pathol. 1-8. https://doi.org/10.1044/2017_AJSLP-16-0098
• 35 Eadie TL. The ICIDH-2: theoretical and clinical implications for speech-language pathology. J Speech Lang Pathol Audiol 2001; 25: 181-200
• 36 World Health Organization. ICF: International Classification of Functioning, Disability and Health. Geneva: Author; 2001
• 37 Eadie TL, Yorkston KM, Klasner ER. , et al. Measuring communicative participation: a review of self-report instruments in speech-language pathology. Am J Speech Lang Pathol 2006; 15 (04) 307-320
• 38 Hustad KC. Optimizing communicative effectiveness: bringing it together. In: Yorkston K, Beukelman D, Strand EA, Bell KR. , eds. Management of Motor Speech Disorders in Children and Adults. Austin, TX: Pro-Ed; 1999: 483-537
• 39 Yorkston KM, Baylor CR, Dietz J. , et al. Developing a scale of communicative participation: a cognitive interviewing study. Disabil Rehabil 2008; 30 (06) 425-433
• 40 World Health Organization. ICIDH: International Classification of Impairments, Disability and Handicap. Geneva: Author; 1980
• 41 Paul D, Frattali C, Holland A, Thompson C, Caperton C, Slater S. Quality of Communication Life Scale (ASHA QCL). Rockville, MD: ASHA 2004
• 42 Dowling M. From Husserl to van Manen. A review of different phenomenological approaches. Int J Nurs Stud 2007; 44 (01) 131-142
• 43 Siegel L. The Consequences of Oromandibular Dystonia on Communicative Participation: A Qualitative Study of the Insider's Experiences [master's thesis]. London: Western University; 2016
• 44 Ma EP, Yiu EM. Voice activity and participation profile: assessing the impact of voice disorders on daily activities. J Speech Lang Hear Res 2001; 44 (03) 511-524
• 45 Yorkston K, Beukelman D, Tice R. Speech Intelligibility Test. Lincoln, NE: Institute for Rehabilitation Science and Engineering at Madonna Rehabilitation Hospital; 2011
• 46 Donovan NJ, Velozo CA, Rosenbek JC. The Communicative Effectiveness Survey: investigating its item-level psychometric properties. J Med Speech-Lang Pathol 2007; 15: 433-447
• 47 Yorkston KM, Klasner ER, Swanson KM. Communication in context: a qualitative study of the experiences of individuals with multiple sclerosis. Am J Speech Lang Pathol 2001; 10 (02) 126-137
• 48 Charous SJ, Comella CL, Fan W. Jaw-opening dystonia: quality of life after botulinum toxin injections. Ear Nose Throat J 2011; 90 (02) E9-E12
• 49 Nastasi L, Mostile G, Nicoletti A, Zappia M, Reggio E, Catania S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol 2016; 263 (09) 1702-1708
• 50 Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D. The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. J Speech Lang Hear Res 2013; 56 (04) 1190-1208
• 51 Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 1999; 13 (04) 557-569
• 52 Jacobson BH, Johnson A, Grywalski C, Silbergliet A, Jacobson G, Benninger MS. Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 1997; 6 (03) 66-69
• 53 Piacentini V, Zuin A, Cattaneo D, Schindler A. Reliability and validity of an instrument to measure quality of life in the dysarthric speaker. Folia Phoniatr Logop 2011; 63 (06) 289-295